

Date: 2010-Jan-13

To: Centre Representatives
 Ethics Representatives
 Contact Clinical Research Associates

From: Anna Sadura, Trial Management, NCIC Clinical Trials Group

**RE: PERMANENT TRIAL CLOSURE NOTICE FOR
 PHASE I/II/III INTERGROUP LED STUDIES**

Dear Participants,

We are writing today to inform you of the results of our annual Permanent Trial Closure Assessment for Intergroup led studies. This annual process includes two components: assessment of trials led by NCIC CTG and assessment of trials led by intergroup collaborators. This letter addresses the second of these components. Each of the applicable lead groups has identified the following Intergroup-led trials that are complete and no longer require action. Please find these trials listed below. "No longer require action" includes cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals. We are hopeful that the permanent closure of trials that have met all study endpoints and that no longer warrant data collection will reduce the workload for participating centres.

Effective immediately, data submission and REB approval for the following Intergroup- led trials is no longer required:

<i>Disease Site</i>	<i>Trial Code</i>	<i>Contact</i>
Brain	CE.3 (26981)	Marina Djurfeldt mdjurfeldt@ctg.queensu.ca
Breast	MA.9C (8854)	Christine Bertrim cbertrim@ctg.queensu.ca
Gastrointestinal	CO.15 (89803)	Patrick Smith psmith@ctg.queensu.ca
Genitourinary	PR.5 (PR.5)	Christine Bertrim cbertrim@ctg.queensu.ca
Gynecology	OV.14 (OC9804)	Monica Bacon mbacon@ctg.queensu.ca
Hematology	AL.2 (INT0129)	Christine Bertrim cbertrim@ctg.queensu.ca
Lung	BR.15 (0023) BR.23C (9925) BRC.3 (0124)	Christine Bertrim cbertrim@ctg.queensu.ca Cathy Davidson cdauidson@ctg.queensu.ca Cathy Davidson cdauidson@ctg.queensu.ca
Sarcoma	OS.4 (80861) SRC.5 (0502)	Christine Bertrim cbertrim@ctg.queensu.ca Anne Farley afarley@ctg.queensu.ca

Health Canada and industry partners have been notified of these final trial closures where applicable. Please notify your REB of any outstanding ethics documents for the applicable trials above and of the final completion of these trials. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.

Please note that although these trials are permanently closed, trial documents must still be retained. NCIC CTG will continue to notify participating centres when trial related records no longer need to be retained in accordance with applicable regulations. Please visit the following web site for further information: <http://www.ctg.queensu.ca/private/ethics/RecordsRetention.pdf>

Yours sincerely,

A handwritten signature in black ink, appearing to read "Ania Asadura". The signature is fluid and cursive, with the first name "Ania" and last name "Asadura" clearly distinguishable.

Manager, Trial Conduct
NCIC CTG Clinical Trials Group
asadura@ctg.queensu.ca